TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29974494

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: DBPCFC
Number of subjects: 0
Study: 27191693

Group type: EXPERIMENTAL
Intervention: Concurrent training (15-20 minutes of aerobic exercise plus 40 minutes of resistance exercise), 3 times per week, for 16 weeks.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Concurrent training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study: 24354547

Group type: EXPERIMENTAL
Intervention: Brief intervention as part of a National Institute on Drug Abuse‐funded clinical trial of a screening and brief intervention protocol
Number of subjects: 147
Study: 22692651

Group type: EXPERIMENTAL
Intervention: Internet based, nurse led vascular risk factor management programme promoting self management for 12 months.
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care alone.
Number of subjects: 330
Study: 21096475

Group type: EXPERIMENTAL
Intervention: EEG-based motor imagery brain-computer interface (MI-BCI) with robotic feedback neurorehabilitation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Robotic rehabilitation that delivers movement therapy
Number of subjects: 54
Study: 18407881

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312

Group type: COMPARATOR
Intervention: Vocational Services
Number of subjects: 312
Study: 16022078

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus total mesorectal excision (TME)
Number of subjects: 1302

Group type: COMPARATOR
Intervention: TME only
Number of subjects: 1302
Study: 12052800

Group type: EXPERIMENTAL
Intervention: Daily elemental zinc (10 mg for infants, 20 mg for older children)
Number of subjects: 2482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2482
Study: 10607811

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 900
Study: 9180409

Group type: EXPERIMENTAL
Intervention: Hydrosystem (topical surfactant)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 50
Study: 1860291

Group type: EXPERIMENTAL
Intervention: Herbal/Bicarbonate Toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study: 6350475

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (ACV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30801889

Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Standard Hysteroscopy
Number of subjects: 1597
Study: 28732435

Group type: EXPERIMENTAL
Intervention: Oral levamisole (50 mg twice a day for two weeks with each vaccination)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 25806661

Group type: EXPERIMENTAL
Intervention: Standard DBT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DBT-S
Number of subjects: 99

Group type: COMPARATOR
Intervention: DBT-I
Number of subjects: 99
Study: 24821457

Group type: EXPERIMENTAL
Intervention: Lipoic acid (1,200 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22292370

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phentolaminum
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (routine nursing treatment)
Number of subjects: 200
Study: 19207720

Group type: EXPERIMENTAL
Intervention: MI + perindopril + losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: MI + perindopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: MI + losartan
Number of subjects: 0
Study: 17259403

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 3534

Group type: EXPERIMENTAL
Intervention: KCNJ11 E23K variant
Number of subjects: 3534

Group type: EXPERIMENTAL
Intervention: ABCC8 A1369S variant
Number of subjects: 3534
Study: 15238983

Group type: EXPERIMENTAL
Intervention: Nurse-led early discharge
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional stay
Number of subjects: 108
Study: 11593938

Group type: EXPERIMENTAL
Intervention: High emotional intensity condition
Number of subjects: 170

Group type: COMPARATOR
Intervention: Low emotional intensity condition
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Valence properties varied condition
Number of subjects: 170

Group type: COMPARATOR
Intervention: Affective qualities matched condition
Number of subjects: 170
Study: 9483341

Group type: EXPERIMENTAL
Intervention: In-room calendars (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No calendars (n = 16)
Number of subjects: 30
Study: 8034816

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral mood management intervention (10 group sessions over 8 weeks)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard treatment (5 group sessions over 8 weeks)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 149
Study: 2589581

Group type: EXPERIMENTAL
Intervention: Education program (Group 1, 103 patients, 203 limbs)
Number of subjects: 203

Group type: COMPARATOR
Intervention: No education (Group 2, 100 patients, 193 limbs)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Education program (Group 1)
Number of subjects: 203

Group type: COMPARATOR
Intervention: No education (Group 2)
Number of subjects: 203
Study: 30099400

Group type: EXPERIMENTAL
Intervention: Prophylactic manual ventilation using a bag-valve-mask device
Number of subjects: 400

Group type: COMPARATOR
Intervention: No prophylactic ventilation
Number of subjects: 400
Study: 26535872

Group type: EXPERIMENTAL
Intervention: 150,000 IU vitamin D3
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25505257

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study: 23290128

Group type: EXPERIMENTAL
Intervention: Self-reported dizziness
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Perceived fatigue
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Recurring falls
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Excessive drowsiness
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Final model discrimination
Number of subjects: 391
Study: 20051714

Group type: EXPERIMENTAL
Intervention: Substance P (10(‐5) mol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance P (10(‐6) mol/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 18652840

Group type: EXPERIMENTAL
Intervention: Tailored print-based intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study: 16109077

Group type: EXPERIMENTAL
Intervention: 250 mg oral ascorbic acid 3x/week for 8 weeks (n=10)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 250 mg intravenous ascorbic acid 3x/week for 8 weeks (n=11)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 500 mg oral ascorbic acid 3x/week for 3 months (n=70)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No treatment (n=83)
Number of subjects: 153
Study: 12374323

Group type: EXPERIMENTAL
Intervention: Conditionals of the form If A then C and If A then possibly C
Number of subjects: 0
Study: 10425594

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of ondansetron
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of dimenhydrinate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11837089

Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdentures
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional mandibular denture (mucosa-borne)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture retained by two IMZ-implants (implant-mucosa-borne)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mandibular overdenture on a transmandibular implant (TMI; mainly implant-borne)
Number of subjects: 3
Study: 2255749

Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6452987

Group type: EXPERIMENTAL
Intervention: Meclocycline sulfosalicylate cream, 1 percent, applied twice daily
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Meclocycline sulfosalicylate cream, 1 percent
Number of subjects: 351
Study: 31021451

Group type: EXPERIMENTAL
Intervention: Model-free digital workflow using digital impressions immediately after implant placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hybrid workflow using conventional impressions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Model-free digital workflow
Number of subjects: 40
Study: 28339999

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 120
Study: 25595417

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8888

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8888

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 8888
Study: 23343690

Group type: EXPERIMENTAL
Intervention: Left Radial Access (LRA)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Right Radial Access (RRA)
Number of subjects: 413
Study: 21118309

Group type: EXPERIMENTAL
Intervention: Methotrexate (initial dose, 15 mg per week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclosporine (initial dose, 5 mg per kg of bodyweight per day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 37
Study: 19117328

Group type: EXPERIMENTAL
Intervention: Therapist supervised training group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Self‐directed training group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 18326780

Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey on ARS use
Number of subjects: 0
Study: 15336614

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12082657

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 4,000 to 10,000 IU by subcutaneous injection 3 times weekly
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral indomethacin 50 mg twice daily (Control group)
Number of subjects: 108
Study: 9681078

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg once daily
Number of subjects: 555

Group type: COMPARATOR
Intervention: Aminoglutethimide 250 mg twice daily
Number of subjects: 555
Study: 8006395

Group type: EXPERIMENTAL
Intervention: Prednisone (0.6 to 0.3 mg/kg per day for 1 month) followed by interferon alfa‐2a (3 MU/m2, thrice weekly, for 12 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 43
Study: 2456731

Group type: EXPERIMENTAL
Intervention: Chlorproguanil with folate supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maloprim with folate supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorproguanil without folate supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29668608

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg (group D1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 μg/kg (group D2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg/kg (group D3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control group R)
Number of subjects: 100
Study: 29133488

Group type: EXPERIMENTAL
Intervention: SMS reminders for influenza vaccination
Number of subjects: 6177

Group type: COMPARATOR
Intervention: No SMS reminders (control)
Number of subjects: 6177

Group type: EXPERIMENTAL
Intervention: SMS reminders for children younger than 5 years
Number of subjects: 6177
Study: 26262276

Group type: EXPERIMENTAL
Intervention: 3-D CPR game
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 23438411

Group type: EXPERIMENTAL
Intervention: Forgiveness intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 78
Study: 21307769

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (5, 6, 7, 8, 9, 10, or 11 mg) coadministered with 200 μg morphine and 10 μg fentanyl
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (low doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine
Number of subjects: 42
Study: 19190211

Group type: EXPERIMENTAL
Intervention: Primaquine 0.58 mg/kg/d
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Primaquine 0.83 mg/kg/d
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Primaquine 1.17 mg/kg/d
Number of subjects: 112
Study: 16794504

Group type: EXPERIMENTAL
Intervention: 6 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine) + 2550 cGy involved‐field radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early complete response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy and chemoradiotherapy
Number of subjects: 0
Study: 12759862

Group type: EXPERIMENTAL
Intervention: DCR with excision of the posterior sac mucosal flap (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: DCR without excision of the posterior sac mucosal flap (Group A)
Number of subjects: 80
Study: 11938825

Group type: EXPERIMENTAL
Intervention: Shenlong Oral Liquid (SLOL) combined with radiotherapy
Number of subjects: 60
Study: 9506009

Group type: EXPERIMENTAL
Intervention: Investigational transdermal testosterone systems
Number of subjects: 19
Study: 8402806

Group type: EXPERIMENTAL
Intervention: Single application of 40% chlorhexidine varnish
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Repeated application of 40% chlorhexidine varnish (two applications)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo varnish (control group)
Number of subjects: 29
Study: 3618133

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment preoperatively
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (no preoperative treatment)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Cases where CT was not detected
Number of subjects: 288
Study: 29634491

Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 189

Group type: COMPARATOR
Intervention: Supraclavicular block
Number of subjects: 189

Group type: COMPARATOR
Intervention: Anterior suprascapular block
Number of subjects: 189
Study: 28577668

Group type: EXPERIMENTAL
Intervention: Model derived from ASCEND-HF trial cohort (n=4,767)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Validation cohort (n=666)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Final 10-variable clinical prediction model
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Adding ischemic heart failure, troponin, and B-type natriuretic peptide
Number of subjects: 666
Study: 26280823

Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO) 50 mL daily for 20 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO) 50 mL daily for 20 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Number of subjects: 39
Study: 23766338

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy 400/100 mg twice daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Triple therapy (zidovudine/lamivudine 300/150 mg twice daily)
Number of subjects: 105
Study: 20638827

Group type: EXPERIMENTAL
Intervention: Re-esterified triglycerides
Number of subjects: 72

Group type: COMPARATOR
Intervention: Natural fish oil
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ethyl esters
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Free fatty acids
Number of subjects: 72

Group type: COMPARATOR
Intervention: Natural triglycerides
Number of subjects: 72
Study: 18830521

Group type: EXPERIMENTAL
Intervention: Microspirometry
Number of subjects: 611
Study: 19911247

Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia (study group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: General anesthesia alone (control group)
Number of subjects: 99
Study: 15877670

Group type: EXPERIMENTAL
Intervention: Intravenous iron (125 mg of ferric gluconate per treatment)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no iron administration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous iron and Control
Number of subjects: 19
Study: 12145220

Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg glibenclamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All three drugs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 24
Study: 9521834

Group type: EXPERIMENTAL
Intervention: Liking judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disliking judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brighter and darker judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior exposure to novel shapes
Number of subjects: 0
Study: 7809806

Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 58
Study: 3393916

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, bleomycin, and methotrexate/leucovorin (PBM) before local regional treatment
Number of subjects: 224

Group type: COMPARATOR
Intervention: Induction chemotherapy with cisplatin and infusion 5-fluorouracil
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PBM after surgery and/or radiotherapy
Number of subjects: 224
Study: 30586750

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 25096

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25096
Study: 28198196

Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Emotional awareness module
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cognitive flexibility module
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors module
Number of subjects: 8
Study: 27557300

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 6693

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6693
Study: 24300595

Group type: EXPERIMENTAL
Intervention: Whey supplementation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Casein supplementation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control carbohydrate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET)
Number of subjects: 33
Study: 22982082

Group type: EXPERIMENTAL
Intervention: Triple P Online (TPOL) intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Internet-use-as-usual control group
Number of subjects: 116
Study: 19220672

Group type: EXPERIMENTAL
Intervention: Allowed to drink water for up to one hour prior to endoscopy (group B)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nil by mouth for 6 h prior to endoscopy (group A)
Number of subjects: 128
Study: 17325557

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (1.0 g/kg/d amino acids starting within the first day and 1.0 g/kg/d lipid added the next day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional nutrition (10% glucose and electrolytes in the first 72 hours, followed by 0.5 g/kg/d amino acids and lipid)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional nutrition
Number of subjects: 72
Study: 14741063

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenously over 30 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 18
Study: 11480793

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 600 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no ascorbic acid)
Number of subjects: 62
Study: 9747403

Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-specific counselling
Number of subjects: 74
Study: 7826055

Group type: EXPERIMENTAL
Intervention: 200-ml milkshake preload
Number of subjects: 133

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 133
Study: 3046889

Group type: EXPERIMENTAL
Intervention: Brand A levothyroxine sodium tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brand B levothyroxine sodium tablets
Number of subjects: 0
Study: 29663458

Group type: EXPERIMENTAL
Intervention: Vaccine schedule A (0, 1, and 2 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vaccine schedule B (0, 1, and 6 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vaccine schedule C (0, 1, and 12 months)
Number of subjects: 46
Study: 26898567

Group type: EXPERIMENTAL
Intervention: MTA root-end filling
Number of subjects: 52

Group type: COMPARATOR
Intervention: Gutta-percha filling smoothing
Number of subjects: 52
Study: 24632495

Group type: EXPERIMENTAL
Intervention: Normoxia (21% O2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypoxia with restraint of respiratory chemoreflex
Number of subjects: 8